Synergistic growth inhibition of prostate cancer cells by 1α,25 Dihydroxyvitamin D3 and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A

Oncogene

Volumn 20, Issue 15, 2001, Pages 1860-1872

  Rashid, Samantha F ^a   Moore, Jasbir S ^a   Walker, Elizabeth ^a   Driver, Philip M ^a   Engel, Jaqueline ^a   Edwards, Ceri E ^a   Brown, Geoffrey ^a   Uskokovic, Milan R ^b   Campbell, Moray J ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

1 ,25 Dihydroxyvitamin D3; Apoptosis; Growth inhibition; Histone deacetylation inhibitors; Prostate cancer

Indexed keywords

BUTYRIC ACID; CALCITRIOL; CALCITRIOL DERIVATIVE; HISTONE DEACETYLASE; PROTEIN P21; TRICHOSTATIN A; VITAMIN RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL DIFFERENTIATION; CONTROLLED STUDY; DEACETYLATION; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MALE; MITOSIS INHIBITION; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BUTYRIC ACID; CALCITRIOL; CELL CYCLE; CHOLECALCIFEROL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG SYNERGISM; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MALE; PROSTATIC NEOPLASMS; STEROID HYDROXYLASES; TRANS-ACTIVATION (GENETICS); TUMOR CELLS, CULTURED;

EID: 0035810045     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1204269     Document Type: Article

References (66)